Efficacy of rituximab in autoimmune hemolytic anemia associated with splenic marginal zone lymphoma

Abstract

et al.. Efficacy of rituximab in autoimmune hemolytic anemia associated with splenic marginal zone lymphoma.

Use of Rituximab in Autoimmune Hemolytic Anemia Associated with Non-Hodgkin Lymphomas

“…Ten years ago, rituximab has been frequently employed in AHA occurring in chronic lymphocytic leukemia (CLL) [ 30 ], and its use has been recently incorporated in the guidelines from the International Workshop on CLL [ 31 ]. The experience in using rituximab in NHL patients with AHA is much less robust and so far, besides some reports on patients with concomitant CAD and lymphoproliferative disorders [ 32 – 34 ], ten single cases have been reported between 1998 and 2009 [ 20 – 29 ], as shown in Table 1 . The more frequent histological patterns are lymphoplasmacytic [ 22 – 24 ] and marginal zone NHL [ 20 , 25 – 27 , 29 ], described in 4 and 5 cases respectively.…”

“…The experience in using rituximab in NHL patients with AHA is much less robust and so far, besides some reports on patients with concomitant CAD and lymphoproliferative disorders [ 32 – 34 ], ten single cases have been reported between 1998 and 2009 [ 20 – 29 ], as shown in Table 1 . The more frequent histological patterns are lymphoplasmacytic [ 22 – 24 ] and marginal zone NHL [ 20 , 25 – 27 , 29 ], described in 4 and 5 cases respectively. A patient with splenic T-cell angioimmunoblastic NHL has been also described, representing the only reported case in which rituximab was unsuccessful [ 28 ].…”